FREE SHIPPING ON ORDERS $70+FAST U.S. FULFILLMENTBATCH DOCUMENTATION

BPC-157 vs TB-500: A Research Overview of Two Widely Studied Peptides

By The Bionova Club Team

Disclosure: Bionova Club sells BPC-157, TB-500 and a BPC-157 + TB-500 blend, linked below.

Research use only. All Bionova products are sold strictly for in-vitro and laboratory research by qualified professionals. They are not drugs, food, or cosmetics, are not approved by the FDA, and are not for human or veterinary use. Nothing in this article is medical advice or a claim about effects in people.

BPC-157 and TB-500 are two of the most frequently searched research peptides, and they are often discussed together. That makes it easy to assume they are related, or interchangeable. They are neither. They come from different parent molecules, have different sizes and sequences, and the literature studies them through different mechanisms.

This overview sets out what each compound is, what the published research has examined, where the two overlap, and why pre-blended vials such as our BPC-157 + TB-500 blend exist.

BPC-157 vs TB-500 at a glance

  • Parent molecule
    • BPC-157: Described as a fragment of "body protection compound," a protein reported in human gastric juice
    • TB-500: Derived from thymosin beta-4 (Tβ4), a protein found in nearly all cells
  • Length
    • BPC-157: 15 amino acids
    • TB-500: 7 amino acids (Ac-LKKTETQ) in the anti-doping literature (Ho et al., 2012); Bionova's TB-500 product is identified as full-length Tβ4, 43 amino acids
  • Sequence
    • BPC-157: GEPPPGKPADDAGLV
    • TB-500: Fragments are built around Tβ4's actin-binding region; LKKTETQ is Tβ4 residues 17–23 (Ho et al., 2012)
  • Molecular weight
    • BPC-157: ~1,419.5 g/mol
    • TB-500: ~4,963 g/mol for full-length Tβ4; much lower for short fragments
  • CAS number
  • Main mechanisms studied
    • BPC-157: Angiogenesis-related signaling, growth-factor pathways, fibroblast migration
    • TB-500: G-actin sequestration, cytoskeletal regulation, cell migration
  • Typical research models
    • BPC-157: Gastrointestinal, tendon, ligament and vascular models in rodents; cell culture
    • TB-500: Wound, corneal, cardiac and vascular models; cell culture
  • Supplied as
    • BPC-157: Lyophilized powder
    • TB-500: Lyophilized powder

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide, meaning it is 15 amino acids long. It is usually described as a partial sequence of a larger protein reported in gastric juice, which is why much of the early literature sits in gastrointestinal research. It is also known in the literature as PL 14736 and Bepecin.

What has BPC-157 research examined?

Most published BPC-157 work is preclinical, meaning it was done in cell culture or animal models. A 2018 review by Seiwerth and colleagues summarizes this literature, focusing on how BPC-157 has been studied alongside standard angiogenic growth factors in gastrointestinal, tendon, ligament, muscle and bone models (Seiwerth et al., 2018, Current Pharmaceutical Design).

At the cellular level, an ex vivo and in vitro study by Chang and colleagues used rat Achilles tendon explants and tendon fibroblasts. It measured tendon outgrowth, cell survival and cell migration (Chang et al., 2011, Journal of Applied Physiology).

A 2025 systematic review screened the BPC-157 literature from an orthopaedic perspective and included 36 studies. Of those, 35 were preclinical, and the authors noted that clinical safety data were lacking (Vasireddi et al., 2025, HSS Journal).

What is TB-500?

TB-500 is the name commonly used for a synthetic peptide related to thymosin beta-4 (Tβ4). Tβ4 itself is a 43-amino-acid protein present in nearly all human and animal cells. It is one of the main proteins that binds monomeric (G-) actin.

Why the name "TB-500" can be confusing

"TB-500" does not always name the same molecule. In anti-doping literature it is a short synthetic fragment built around Tβ4's actin-binding region (Ho et al., 2012). Bionova uses the name for full-length Tβ4. A 2026 scoping review of the Tβ4 and TB-500 literature included 80 studies. It found that most of them evaluated Tβ4 rather than TB-500, and that direct TB-500 evidence was limited to a single included study (McGuire et al., 2026, Applied Sciences). When comparing papers, always check which molecule was actually used.

What has thymosin beta-4 research examined?

Tβ4's best-characterized role is in actin biology. Early work showed that Tβ4 is the same molecule as a previously described actin-sequestering peptide (Safer et al., 1991, Journal of Biological Chemistry). Later work found that it sequesters most of the unpolymerized actin in resting human neutrophils (Cassimeris et al., 1992, Journal of Cell Biology).

Because actin dynamics underpin how cells move and change shape, Tβ4 has since been studied in cell-migration, angiogenesis, wound, corneal and cardiac models. A widely cited review by Goldstein and colleagues covers its basic properties and the research programs built on them (Goldstein et al., 2012, Expert Opinion on Biological Therapy).

Key differences between BPC-157 and TB-500

Origin and structure

BPC-157 is a short, linear 15-mer with a fixed, widely agreed sequence. TB-500 is defined by its relationship to Tβ4, and its exact structure depends on the supplier's definition. That difference alone matters for reproducibility. A BPC-157 result is easier to tie to a specific molecule than a "TB-500" result.

Mechanisms studied

The two literatures focus on different biology:

  • BPC-157: research centers on angiogenesis-related signaling (including nitric oxide and VEGF-related pathways), growth-factor interactions, and fibroblast behavior.
  • TB-500 / Tβ4: research centers on actin sequestration and cytoskeletal regulation, which affect cell migration and tissue organization.

The shared ground is angiogenesis and cell migration. Both have been examined in vascular and repair-related models, through different proposed pathways. That overlap is why they are so often co-referenced.

Research models

BPC-157 papers lean heavily toward rodent gastrointestinal and musculoskeletal models. Tβ4 papers are more spread out, across wound, ocular and cardiac models, and include registered clinical programs for specific investigational Tβ4 products. None of this makes either compound approved for any use, and neither is approved by the FDA.

Have BPC-157 and TB-500 been studied together?

Direct comparisons are rare. One 2026 exploratory study in rats compared four groups after a standardized Achilles tendon procedure: control, BPC-157, TB-500 (described as synthetic thymosin beta-4), and the two combined. It assessed biomechanical, histological and immunohistochemical measures (Biçer et al., 2026, Joint Diseases and Related Surgery).

The authors reported group differences on several measures, most consistently for the TB-500 group. The combined group did not show an additive difference over either compound alone. They described the work as exploratory and called for further experimental confirmation. As with all animal data, these findings describe one model under specific conditions and cannot be extrapolated to people.

Why researchers use pre-blended BPC-157 + TB-500 vials

Labs that include both compounds in the same experimental design sometimes prefer a single pre-blended vial. It can mean fewer separate items to order and track, and one consistent ratio across experiments. Bionova's BPC-157 + TB-500 blend contains 10 mg of each compound.

Separate vials make more sense when a study design needs independent control of each variable, such as single-compound arms or different ratios. Both are available individually as BPC-157 10 mg and TB-500 10 mg. Our other multi-compound formats are in the research blends category.

Storage

Both peptides are supplied as lyophilized (freeze-dried) material. Like most lyophilized peptides, they are most stable kept sealed in the original container, cold, dry and away from light. Let a sealed container reach room temperature before opening so moisture does not condense on the material. Store as directed on the product label.

Key takeaways

  • BPC-157 and TB-500 are distinct molecules with different origins, sizes and sequences.
  • BPC-157 research focuses on angiogenesis and growth-factor signaling. Tβ4/TB-500 research focuses on actin and cytoskeletal regulation.
  • "TB-500" is not used consistently. Check whether a paper or product refers to a fragment or to full-length Tβ4.
  • The evidence base for both is mostly preclinical, and direct head-to-head studies are rare.
  • Both are research materials only and are not approved for human use.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. Thymosin beta-4 is a 43-amino-acid protein that occurs naturally. "TB-500" is a trade name used for synthetic material related to it: sometimes a short fragment built around the actin-binding region, sometimes full-length Tβ4. Most published research used Tβ4 rather than a TB-500 fragment.

What is the main difference between BPC-157 and TB-500?

They come from different parent molecules and are studied through different mechanisms. BPC-157 is a 15-amino-acid peptide researched mainly in angiogenesis and growth-factor signaling. TB-500 relates to thymosin beta-4 and is researched mainly in actin binding and cell migration.

Has any study compared BPC-157 and TB-500 directly?

Very few. One 2026 exploratory rat study compared BPC-157, TB-500 and the combination in a tendon model. It reported no additive difference for the combination. It is a single animal study and does not establish effects in people.

Are BPC-157 and TB-500 approved for human use?

No. Neither compound is FDA-approved. Bionova supplies both strictly for in-vitro and laboratory research. They are not for human or veterinary use.

Why would a lab use a BPC-157 and TB-500 blend instead of separate vials?

A pre-blended vial gives a consistent ratio and fewer separate items to track when a study design includes both compounds. Separate vials are better when each compound needs to be varied or tested on its own.

How should BPC-157 and TB-500 be stored?

Keep sealed lyophilized vials cold, dry and protected from light, and let them reach room temperature before opening. Store as directed on the product label.

Shop for your research: BPC-157, TB-500 or the Wolverine (BPC-157 + TB-500) blend, for laboratory research. Use code CLUB10 at checkout for 10% off.

References

  1. Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018. https://pubmed.ncbi.nlm.nih.gov/29998800/
  2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. https://pubmed.ncbi.nlm.nih.gov/21030672/
  3. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
  4. Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. https://pubmed.ncbi.nlm.nih.gov/1999398/
  5. Cassimeris L, et al. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992. https://pubmed.ncbi.nlm.nih.gov/1447300/
  6. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
  7. McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. 2026. https://doi.org/10.3390/app16126202
  8. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Dis Relat Surg. 2026;37(3). https://www.jointdrs.org/full-text/1851
  9. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. https://pubmed.ncbi.nlm.nih.gov/23084823/

For laboratory research use only. Not for human consumption.